Alamar Biosciences, Inc.(ALMR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ALMR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Alamar Biosciences, Inc. (ALMR), a Technology sector company. ALMR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Alamar Biosciences, Inc. reports quarterly revenue of $26.0M, net income of $-21.3M, an operating margin of -47.4%. ALMR trades on the Nasdaq exchange and files with the SEC under CIK 2104204. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALMR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alamar Biosciences, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$26.0M
Net Income
Q1 2026
$-21.3M
Free Cash Flow
Q1 2026
$-20.9M
Operating Margin
Q1 2026
-47.4%
AI Insight: ALMR Ratio Trends
Single-quarter snapshot only — Alamar Biosciences shows deeply negative margins with no multi-period trend data available.
• Operating margin stood at -47.4% and net profit margin at -81.9% in Q1 2026, signaling heavy cash burn relative to revenue.
• ROA of -45.8% in Q1 2026 indicates assets are generating significant losses; ROE, ROIC, and D/E are unavailable.
⚠ Only one quarter of data exists — no trend direction can be established; subsequent quarters are critical to assess trajectory.
⚠ Missing D/E and ROIC data obscures leverage and capital efficiency picture — watch for disclosure in coming filings.
Get alerted when ALMR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Alamar Biosciences, Inc. including:
More Technology Companies
View all Technology →Put ALMR on your watchlist
Track score changes the day Alamar Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALMR a good stock to buy?
13F Pro's AI-powered analysis of Alamar Biosciences, Inc. (ALMR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALMR are available on the ALMR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ALMR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALMR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alamar Biosciences, Inc.'s investment landscape.